Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod
14th November 2025 Uncategorised 0The FDA said Thursday that it has approved Organon and Henlius Biotech’s Poherdy as an interchangeable biosimilar to Perjeta. The approval covers the Roche drug’s existing HER2-positive breast cancer indications.
More: Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod
Source: fierce